Odyssey Thera Inks Multiple Agreements With Big Pharma Companies for PCA Assays | GenomeWeb

Pharmaceutical companies are increasing their usage of cell-based assays to determine what effect — positive or negative — their lead compounds have on a variety of cell types.

In some cases, pharmaceutical companies have the expertise to develop such assays in house, but some have begun to look for outside partnerships with companies that specialize in developing cell-based assays and high-throughput screening processes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.